Customer Publication

Oncogenic signals prime cancer cells for toxic cell overgrowth during a G1 cell cycle arrest

Authors: Foy R et al.

Journal: Molecular cell (2023)

Research Areas: Cancer Research

Cell Lines: RPE, MCF7 and T47D (retinal pigment epithelium and breast cancer cell line)

Summary: CDK4/6 inhibitors are remarkable anti-cancer drugs that can arrest tumor cells in G1 and induce their senescence while causing only relatively mild toxicities in healthy tissues. How they achieve this mechanistically is unclear. This article shows that tumor cells are specifically vulnerable to CDK4/6 inhibition because during the G1 arrest, oncogenic signals drive toxic cell overgrowth. This overgrowth causes permanent cell cycle withdrawal by either preventing progression from G1 or inducing genotoxic damage during the subsequent S-phase and mitosis. Inhibiting or reverting oncogenic signals that converge onto mTOR can rescue this excessive growth, DNA damage, and cell cycle exit in cancer cells. Conversely, inducing oncogenic signals in non-transformed cells can drive these toxic phenotypes and sensitize the cells to CDK4/6 inhibition. Together, this demonstrates that cell cycle arrest and oncogenic cell growth is a synthetic lethal combination that is exploited by CDK4/6 inhibitors to induce tumor-specific toxicity. HoloMonitor is used to study the cell volume change.

Keywords: HoloMonitor M4, cell morphology, CDK4/6, oncogenes, cell growth, cell cycle, growth factors, chemotherapy, breast cancer, p53, p21, replication stress

Read the article …